Association of Angiotensin I Converting Enzyme Insertion/287 bp Deletion Polymorphisms and Proliferative Prostatic Diseases among Lebanese Men

Table 3

The frequencies of the genotypes II, ID, and DD of the control and the subjects with PCa or BPH.

Allele	Control	Affected	OR	95% CI	value	RR	95% CI	value
A. Control group versus PCa group
DD/II	27/8	19/7	0.80	0.25–2.60	0.716	0.95	0.71–1.27	0.719
DD/ID	27/34	19/43	0.56	0.27–1.17	0.120	0.69	0.43–1.11	0.124
(DD + ID)/II	61/8	62/7	1.16	0.40–3.40	0.785	1.02	0.90–1.14	0.785
(II + ID)/DD	42/27	50/19	1.69	0.83–3.46	0.150	1.19	0.94–1.51	0.152
ID/(DD + II)	34/35	43/26	1.70	0.86–3.35	0.124	1.26	0.94–1.71	0.127
B. Control group versus BPH group
DD/II	27/8	20/1	5.93	0.68–51.27	0.106	1.23	1.00–1.51	0.043
DD/ID	27/34	20/48	0.52	0.25–1.08	0.082	0.66	0.42–1.06	0.084
(DD + ID)/II	61/8	68/1	8.92	1.08–73.37	0.042	1.11	1.02–1.22	0.018
(II + ID)/DD	42/27	49/20	1.58	0.77–3.20	0.210	1.17	0.92–1.49	0.212
ID/(DD + II)	34/35	48/21	2.35	1.17–4.72	0.016	1.41	1.06–1.88	0.018
C. Control group versus the combined PCa and BPH (affected) groups
DD/II	27/8	39/8	1.44	0.48–4.32	0.512	1.08	0.86–1.34	0.520
DD/ID	27/34	39/91	0.54	0.29–1.01	0.055	0.68	0.46–0.99	0.048
(DD + ID)/II	61/8	130/8	2.13	0.76–5.95	0.148	1.07	0.97–1.17	0.190
(II + ID)/DD	42/27	99/39	1.63	0.88–3.00	0.115	1.18	0.95–1.46	0.136
ID/(DD + II)	34/35	91/47	1.99	1.10–3.59	0.021	1.34	1.02–1.75	0.032

Significant at the 0.05 level of significance.